|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Isradipine#Drug Interactions]] |
| {{Isradipine}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| '''Nitroglycerin''': Isradipine has been safely coadministered with [[nitroglycerin]].
| |
| | |
| '''Hydrochlorothiazide''': A study in normal healthy volunteers has shown that concomitant administration of isradipine and [[hydrochlorothiazide]] does not result in altered pharmacokinetics of either drug. In a study in hypertensive patients, addition of isradipine to existing [[hydrochlorothiazide]] therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect.
| |
| | |
| '''Propranolol''': In a single dose study in normal volunteers, co-administration of [[propranolol]] had a small effect on the rate but no effect on the extent of isradipine bioavailability. Significant increases in AUC (27%) and Cmax (58%) and decreases in tmax (23%) of [[propranolol]] were noted in this study. However, concomitant administration of 5 mg b.i.d. isradipine and 40 mg b.i.d. [[propranolol]] to healthy volunteers under steady-state conditions had no relevant effect on either drug’s bioavailability. AUC and Cmax differences were <20% between isradipine given singly and in combination with [[propranolol]], and between [[propranolol]] given singly and in combination with isradipine.
| |
| | |
| '''Cimetidine''': In a study in healthy volunteers, a one-week course of [[cimetidine]] at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%). If isradipine therapy is initiated in a patient currently receiving cimetidine, careful monitoring for adverse reactions is advised and downward dose adjustment may be required.
| |
| | |
| '''Rifampicin''': In a study with healthy volunteers, a six-day course of [[rifampicin ]]at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits. If [[rifampicin ]]therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.
| |
| | |
| '''Warfarin''': In a study with healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic [[warfarin]] was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multiple-dose treatment with 5 mg b.i.d. isradipine. Neither racemic warfarin nor isradipine binding to plasma proteins in vitro was altered by the addition of the other drug.
| |
| | |
| '''Digoxin''': The concomitant administration of isradipine and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of [[digoxin]].
| |
| | |
| '''Fentanyl Anesthesia''': Severe [[hypotension]] has been reported during fentanyl anesthesia with concomitant use of a [[beta-blocker]] and a [[calcium channel blocker]]. Even though such interactions have not been seen in clinical studies with isradipine, an increased volume of circulating fluids might be required if such an interaction were to occur.
| |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ISRADIPINE CAPSULE [COBALT LABORATORIES] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf3425e0-428d-4bdb-ac9a-3b9d483df83a | publisher = | date = | accessdate = 28 February 2014 }}</ref>
| |
| | |
| ==References ==
| |
| {{Reflist|2}}
| |
| | |
| [[Category:Calcium channel blockers]]
| |
| [[Category:Dihydropyridines]]
| |
| [[Category:Benzoxadiazoles]]
| |
| [[Category:Carboxylate esters]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |